NovaSight's CureSight Proves Long-Term Effectiveness In Amblyopia Treatment

NovaSight, a company dedicated to advancing pediatric eye care, has recently shared compelling findings in the American Journal of Ophthalmology regarding its innovative at-home treatment for amblyopia, commonly known as lazy eye. The treatment, named CureSight, has been shown to significantly improve visual acuity and stereoacuity in children. This study highlights the effectiveness of CureSight compared to traditional eye patching methods, marking a significant stride in amblyopia care.

The research conducted across six medical centers, including the renowned Sheba Medical Center, revealed that children undergoing short-term binocular treatment with CureSight experienced notable improvements in visual functions. These improvements were not only significant shortly after the treatment but were also sustained for at least one year. A follow-up study further confirmed these results, showing that the gains in visual acuity and stereoacuity were maintained over time, with a slight reduction after one year but still significantly better than before the treatment.

CureSight leverages advanced eye-tracking technology and algorithms to adjust the visual input received by each eye. By blurring the image seen by the stronger eye and keeping the image for the amblyopic eye clear, it encourages the brain to use both eyes together. This FDA-cleared and CE-marked digital treatment program allows patients to undergo therapy at home by watching streamed content on a tablet, making it a user-friendly option for improving eye health.

Adoption and Real-world Impact

Since receiving FDA clearance in 2022, CureSight has seen significant adoption among eye care providers and patients in the US through the CureSight Referral Program. Over 250 providers have joined, generating more than 650 patient referrals. Real-world data from this program indicates substantial improvements in patients' visual acuity and stereoacuity, with high compliance and satisfaction rates reported.

Future Plans and Funding

NovaSight is gearing up for a full commercial launch of CureSight in the US, Europe, and China by 2024. To support these ambitious plans, the company has initiated a Series B funding round, securing a significant investment from a healthcare-focused venture capital firm. NovaSight will also be presenting at the Annual AAPOS meeting in April to discuss these long-term study results and provide updates on CureSight's progress.

Founded in 2016 in Israel, NovaSight is committed to modernizing pediatric vision care. Alongside CureSight, its portfolio includes EyeSwift PRO for vision assessment and TrackSight for myopia control. These developments underscore NovaSight's dedication to leveraging digital solutions to address common vision problems in children.